NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
Clinical Trials
11 trialsNCT04513522 2025-07-11
CheckMate 7C9
Bristol-Myers Squibb
Phase 4 Completed
NCT03138512 2024-12-18
CheckMate 914
Bristol-Myers Squibb
Phase 3 Completed
NCT03126331 2024-03-18
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02118337 2021-06-01
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies
MedImmune LLC
Phase 1/2 Completed
NCT03065179 2021-03-30
RADVAX
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT03444766 2020-12-04
Study of Nivolumab for Advanced Cancers in India
Bristol-Myers Squibb
Phase 4 Completed
NCT02575222 2020-06-12
Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT02946671 2020-03-06
Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients
Osaka University
Phase 1 Completed
NCT03433534 2019-11-12
NIVEAL
University Hospital, Tours
Completed
NCT00441337 2015-02-20
MDX1106-01
Bristol-Myers Squibb
Phase 1 Completed